Current small molecule options for psoriasis include apremilast, a phosphodiesterase-4 (PDE4) inhibitor, and deucravacitinib, a recently approved tyrosine kinase 2 (TYK2) inhibitor [16,17]. The gene discussed is TYK2; the disease is psoriasis.